Case Studies | Applied XL

Could Irregular Clinical Trial Activity Have Predicted Zuranolone’s MDD Rejection?

AI’s Impact on Drug Design, Regenerative Medicine, and Beyond with Stem Cell Expert Dr. Ermelinda Porpiglia

Introducing AppliedXL’s AI Brand: Elevating Speed & Transparency in Computational Journalism Through Design

Using AI to Improve Decision-Making in Biotech: Insights from MindMed’s Chief Medical Officer

Accelerating Biotech Innovation with AI-Powered Early Risk Detection and Clinical Intelligence

Building AXL-1: The First Language Model Rooted in Journalism and Designed for Biotech

Why we are building a real-time Information company powered by editorial algorithms

Could early red flags in Takeda’s blood cancer program have signaled the failure of their next potential blockbuster?

Could warning signs in Summit Therapeutics’ clinical trial activity have hinted at bad results months before they were announced?

How Feldan Therapeutics uses “kill sheets” to make data driven decisions about clinical development

Did hidden signals in data anticipate bad news for TG Therapeutics' clinical trial for chronic lymphocytic leukemia?

How hidden signals in public data unveiled turmoil in one of the world’s most valuable biotech startups

Early signals in Aileron Therapeutic's ALRN-6924 program hinted at struggles for efficacy over a year before negative results

Did irregular shifts in clinical trial progression at Flagship’s Repertoire foreshadow the termination of its immuno-oncology program?

AppliedXL partners with STAT to launch a new clinical trials monitoring platform powered by artificial intelligence

Bringing you the latest news and data insights from our platform